News

EssilorLuxottica Expects Continued Growth Amid Mixed Market Trends

EssilorLuxottica Expects Continued Growth Amid Mixed Market Trends

EssilorLuxottica Reports Revenue Growth and Future Outlook

EssilorLuxottica (ESLX.PA) has recently announced a 4% revenue increase at constant currency for the third quarter of 2024. This growth contributes to a 4.9% rise in revenue for the first nine months of the year. The company is confident that revenue will accelerate in the fourth quarter thanks to the introduction of new partnerships and innovative product offerings.

Company’s Growth Strategy

The company's revenue target aims for a range of €27 billion to €28 billion by 2026, anticipating mid-single-digit growth year-over-year. Stronger margins are projected for 2024, along with expected FDA clearance for the Stellest product by late 2025 or early 2026. Furthermore, the company plans to expand their subscription model to all optical retail banners by the end of 2025 or the beginning of 2026.

Key Performance Highlights

EssilorLuxottica saw remarkable performance across several regions:

• 4% revenue growth at constant currency in Q3

• Double-digit growth reported in Japan and India

• Strong summer retail season specifically noted in Eastern Europe and Turkey

• Ray-Ban Meta smart glasses emerged as a best-seller in 60% of Ray-Ban stores in Europe

Regional Performance Review

Regionally, the performance varies:

• North America showed slight acceleration, yielding 1.6% growth.

• The EMEA region reported a robust 5.6% growth.

• The Asia Pacific market enjoyed significant performance, particularly in Japan and India.

• Latin America emerged as a major growth driver with a 10.1% increase.

Emerging Trends and Product Launches

Recent product highlights include:

• Strong demand persists for Ray-Ban Meta frames.

• Premium lens brands are excelling in the marketplace.

• Stellest product growth surpasses 70% in the EMEA region.

• Anticipated launch of the Nuance product is expected by early 2024.

Challenges Ahead

While the company experiences strong performance, there are challenges:

• The U.S. and Chinese markets show signs of deceleration in revenue growth.

• There is a noted decrease in demand for sunglasses across North America.

• Professional solutions are encountering difficulties in specific markets such as France, partly due to travel restrictions related to the Olympics.

Future Projections and Expectations

EssilorLuxottica remains optimistic about revenue acceleration in the fourth quarter. The company is positioned to effectively tackle the upcoming holiday season, taking advantage of the strengthened consumer interest. The combination of strategic product innovations, enhanced consumer experiences through subscriptions, and an unwavering commitment to operational excellence signifies the firm's resilience and dedication to future growth.

Frequently Asked Questions

What are the main drivers behind EssilorLuxottica's expected revenue growth?

The primary drivers include new partnerships, innovative product launches, and an expansion of their subscription model across optical retail banners.

How has the company performed in different regions?

EssilorLuxottica has reported strong growth in markets such as Asia Pacific, Japan, and Latin America, while facing challenges in North America and China.

What is the revenue target for EssilorLuxottica by 2026?

The company has set a revenue target of €27 billion to €28 billion by 2026, aiming for consistent mid-single-digit growth.

What challenges is EssilorLuxottica facing in the market?

The company is encountering challenges particularly in the U.S. and China, including softer demand for sunglasses and professional solutions.

When is the anticipated launch of the Stellest product?

The Stellest product is expected to receive FDA clearance by late 2025 or early 2026, expanding its availability in the North American market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 417

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 273

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 410

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 250

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 33

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 126

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 204

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 246

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuits Update for RTO and CUBI Investors

Updated Category News Views 221

Important Class Actions for Shareholders Investors should stay informed about the growing trend of class action lawsuits filed on behalf of shareholders in various publicly-traded companies. These lawsuits often arise from allegations of misleading statements made by the companies' management. Among the latest developments are cases involving Rentokil Initial plc (NASDAQ:...

Continue Reading
TransPerfect's GlobalLink Recognized for Excellence in Localization

Updated Category News Views 75

TransPerfect's GlobalLink Achieves Remarkable Recognition TransPerfect, the premier provider of language and AI solutions for global businesses, has achieved exceptional recognition with its GlobalLink platform. According to the G2 Fall 2024 Report, GlobalLink stands out as a top Enterprise Translation Management Software and Enterprise Website Translation Tool. This...

Continue Reading
Discover the Top U.S. Cities for Affordable Living Choices

Updated Category News Views 337

New Insights on Affordable Living in U.S. Cities A recent survey has ignited discussions on where to find the best cost-effective living environments across the United States. The research indicates a growing need for affordable housing that doesn’t forsake quality of life. In a world where the price of urban living continues to climb, this study by Advance America...

Continue Reading
Hilton USA Trust 2016-SFP CMBS: Navigating Upcoming Changes

Updated Category News Views 261

Understanding the Recent Changes in Hilton USA Trust 2016-SFP CMBS Investors holding the Hilton USA Trust 2016-SFP commercial mortgage pass-through certificates should be aware of significant upcoming changes regarding the special servicer of their loans. Recently, Wells Fargo Bank, N.A. has been involved in the management of these loans, which were placed under special...

Continue Reading
Exclusive CBD Agreement Between Avecho and Sandoz for Insomnia

Updated Category News Views 189

Exclusive Partnership Between Avecho and Sandoz Avecho Biotechnology Limited is thrilled to announce a groundbreaking partnership with Sandoz Group AG. This agreement marks a significant milestone for Avecho as it aims to commercialize its innovative cannabidiol capsule designed specifically for insomnia. With the exclusive license and development agreement now in place,...

Continue Reading